Waters Corporation (0LTI.L)
USD 370.56
(-0.36%)
USD 370.56
(-0.36%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 817.67 Million USD | -3.41% |
| 2022 | 873.39 Million USD | 6.29% |
| 2021 | 821.7 Million USD | 27.3% |
| 2020 | 645.48 Million USD | -8.89% |
| 2019 | 708.45 Million USD | -4.23% |
| 2018 | 739.77 Million USD | 11.77% |
| 2017 | 661.85 Million USD | 6.01% |
| 2016 | 624.33 Million USD | 10.03% |
| 2015 | 567.45 Million USD | 9.57% |
| 2014 | 517.9 Million USD | 0.11% |
| 2013 | 517.34 Million USD | 1.14% |
| 2012 | 511.49 Million USD | -3.24% |
| 2011 | 528.6 Million USD | 17.48% |
| 2010 | 449.93 Million USD | 14.02% |
| 2009 | 394.6 Million USD | 1.24% |
| 2008 | 389.75 Million USD | 11.72% |
| 2007 | 348.87 Million USD | 18.2% |
| 2006 | 295.15 Million USD | 4.24% |
| 2005 | 283.15 Million USD | -0.6% |
| 2004 | 284.85 Million USD | 29.97% |
| 2003 | 219.17 Million USD | 11.59% |
| 2002 | 196.41 Million USD | 31.35% |
| 2001 | 149.52 Million USD | -29.08% |
| 2000 | 210.82 Million USD | 19.45% |
| 1999 | 176.5 Million USD | 29.4% |
| 1998 | 136.4 Million USD | 262.77% |
| 1997 | 37.6 Million USD | -46.51% |
| 1996 | 70.3 Million USD | 24.65% |
| 1995 | 56.4 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 143.88 Million USD | -45.89% |
| 2024 Q3 | 199 Million USD | 10.42% |
| 2024 Q2 | 191.2 Million USD | 32.89% |
| 2023 Q2 | 199.85 Million USD | 14.75% |
| 2023 Q1 | 174.16 Million USD | -39.16% |
| 2023 Q4 | 265.9 Million USD | 48.2% |
| 2023 FY | 843.6 Million USD | -3.41% |
| 2023 Q3 | 179.42 Million USD | -10.22% |
| 2022 Q3 | 192.01 Million USD | -3.82% |
| 2022 Q4 | 286.28 Million USD | 49.1% |
| 2022 FY | 873.39 Million USD | 6.29% |
| 2022 Q1 | 195.47 Million USD | -25.45% |
| 2022 Q2 | 199.63 Million USD | 2.13% |
| 2021 Q4 | 262.2 Million USD | 36.69% |
| 2021 FY | 821.7 Million USD | 27.3% |
| 2021 Q2 | 196.42 Million USD | 14.69% |
| 2021 Q3 | 191.81 Million USD | -2.35% |
| 2021 Q1 | 171.27 Million USD | -35.05% |
| 2020 Q3 | 158.38 Million USD | 2.11% |
| 2020 Q2 | 155.11 Million USD | 127.17% |
| 2020 FY | 645.48 Million USD | -8.89% |
| 2020 Q1 | 68.28 Million USD | -71.12% |
| 2020 Q4 | 263.71 Million USD | 66.5% |
| 2019 Q3 | 173.23 Million USD | -2.49% |
| 2019 FY | 708.45 Million USD | -4.23% |
| 2019 Q1 | 121.15 Million USD | -50.46% |
| 2019 Q2 | 177.65 Million USD | 46.64% |
| 2019 Q4 | 236.41 Million USD | 36.47% |
| 2018 Q4 | 244.53 Million USD | 42.44% |
| 2018 FY | 739.77 Million USD | 11.77% |
| 2018 Q2 | 179.19 Million USD | 24.12% |
| 2018 Q1 | 144.37 Million USD | -37.27% |
| 2018 Q3 | 171.67 Million USD | -4.2% |
| 2017 Q3 | 159.03 Million USD | 3.41% |
| 2017 FY | 661.85 Million USD | 6.01% |
| 2017 Q4 | 230.17 Million USD | 44.73% |
| 2017 Q1 | 118.86 Million USD | -42.94% |
| 2017 Q2 | 153.78 Million USD | 29.37% |
| 2016 Q4 | 208.33 Million USD | 37.31% |
| 2016 Q2 | 151.61 Million USD | 34.57% |
| 2016 Q1 | 112.66 Million USD | -37.86% |
| 2016 FY | 624.33 Million USD | 10.03% |
| 2016 Q3 | 151.73 Million USD | 0.08% |
| 2015 Q1 | 119.98 Million USD | -30.26% |
| 2015 Q3 | 135.84 Million USD | 4.24% |
| 2015 Q4 | 181.3 Million USD | 33.47% |
| 2015 FY | 567.45 Million USD | 9.57% |
| 2015 Q2 | 130.31 Million USD | 8.61% |
| 2014 Q1 | 88.76 Million USD | -49.62% |
| 2014 Q2 | 118.39 Million USD | 33.39% |
| 2014 Q3 | 138.71 Million USD | 17.16% |
| 2014 Q4 | 172.03 Million USD | 24.03% |
| 2014 FY | 517.9 Million USD | 0.11% |
| 2013 FY | 517.34 Million USD | 1.14% |
| 2013 Q4 | 176.17 Million USD | 47.96% |
| 2013 Q1 | 109.4 Million USD | -31.37% |
| 2013 Q3 | 119.06 Million USD | 5.66% |
| 2013 Q2 | 112.69 Million USD | 3.0% |
| 2012 Q1 | 110.21 Million USD | -33.15% |
| 2012 Q2 | 120.12 Million USD | 8.99% |
| 2012 Q3 | 121.74 Million USD | 1.35% |
| 2012 Q4 | 159.4 Million USD | 30.93% |
| 2012 FY | 511.49 Million USD | -3.24% |
| 2011 Q1 | 115.89 Million USD | -21.79% |
| 2011 FY | 528.6 Million USD | 17.48% |
| 2011 Q3 | 127.26 Million USD | 5.55% |
| 2011 Q4 | 164.87 Million USD | 29.55% |
| 2011 Q2 | 120.56 Million USD | 4.03% |
| 2010 Q2 | 105.58 Million USD | 14.32% |
| 2010 FY | 449.93 Million USD | 14.02% |
| 2010 Q4 | 148.17 Million USD | 42.73% |
| 2010 Q3 | 103.81 Million USD | -1.68% |
| 2010 Q1 | 92.35 Million USD | -26.88% |
| 2009 Q4 | 126.3 Million USD | 31.41% |
| 2009 FY | 394.6 Million USD | 1.24% |
| 2009 Q2 | 86.69 Million USD | 1.41% |
| 2009 Q3 | 96.11 Million USD | 10.86% |
| 2009 Q1 | 85.49 Million USD | -26.51% |
| 2008 FY | 389.75 Million USD | 11.72% |
| 2008 Q4 | 116.33 Million USD | 18.67% |
| 2008 Q3 | 98.03 Million USD | 12.65% |
| 2008 Q2 | 87.02 Million USD | -1.52% |
| 2008 Q1 | 88.36 Million USD | -31.98% |
| 2007 Q1 | 72.79 Million USD | -32.0% |
| 2007 Q3 | 69.23 Million USD | -10.02% |
| 2007 Q2 | 76.94 Million USD | 5.7% |
| 2007 Q4 | 129.91 Million USD | 87.65% |
| 2007 FY | 348.87 Million USD | 18.2% |
| 2006 FY | 295.15 Million USD | 4.24% |
| 2006 Q2 | 62.91 Million USD | 5.81% |
| 2006 Q1 | 59.46 Million USD | -37.84% |
| 2006 Q3 | 65.73 Million USD | 4.48% |
| 2006 Q4 | 107.04 Million USD | 62.84% |
| 2005 FY | 283.15 Million USD | -0.6% |
| 2005 Q2 | 66.95 Million USD | 15.67% |
| 2005 Q3 | 62.65 Million USD | -6.42% |
| 2005 Q4 | 95.66 Million USD | 52.69% |
| 2005 Q1 | 57.88 Million USD | -36.66% |
| 2004 FY | 284.85 Million USD | 29.97% |
| 2004 Q1 | 50.8 Million USD | -33.39% |
| 2004 Q2 | 78.9 Million USD | 55.29% |
| 2004 Q3 | 63.76 Million USD | -19.19% |
| 2004 Q4 | 91.38 Million USD | 43.33% |
| 2003 Q4 | 76.27 Million USD | 61.32% |
| 2003 FY | 219.17 Million USD | 11.59% |
| 2003 Q3 | 47.28 Million USD | -10.39% |
| 2003 Q1 | 42.84 Million USD | -23.21% |
| 2003 Q2 | 52.76 Million USD | 23.16% |
| 2002 Q4 | 55.79 Million USD | 13.82% |
| 2002 Q3 | 49.01 Million USD | 2.97% |
| 2002 Q2 | 47.6 Million USD | 7.6% |
| 2002 Q1 | 44.24 Million USD | 5451.19% |
| 2002 FY | 196.41 Million USD | 31.35% |
| 2001 Q1 | 41.17 Million USD | -38.65% |
| 2001 Q2 | 50.57 Million USD | 22.85% |
| 2001 Q4 | 797 Thousand USD | -98.38% |
| 2001 Q3 | 49.11 Million USD | -2.9% |
| 2001 FY | 149.52 Million USD | -29.08% |
| 2000 Q4 | 67.11 Million USD | 30.68% |
| 2000 Q1 | 41.66 Million USD | -28.79% |
| 2000 Q2 | 50.7 Million USD | 21.7% |
| 2000 Q3 | 51.35 Million USD | 1.29% |
| 2000 FY | 210.82 Million USD | 19.45% |
| 1999 Q1 | 34.6 Million USD | -23.96% |
| 1999 FY | 176.5 Million USD | 29.4% |
| 1999 Q4 | 58.5 Million USD | 40.96% |
| 1999 Q3 | 41.5 Million USD | -1.43% |
| 1999 Q2 | 42.1 Million USD | 21.68% |
| 1998 FY | 136.4 Million USD | 262.77% |
| 1998 Q4 | 45.5 Million USD | 35.01% |
| 1998 Q3 | 33.7 Million USD | 8.36% |
| 1998 Q2 | 31.1 Million USD | 19.16% |
| 1998 Q1 | 26.1 Million USD | -21.15% |
| 1997 Q3 | -35.3 Million USD | -264.95% |
| 1997 Q4 | 33.1 Million USD | 193.77% |
| 1997 Q1 | 18.4 Million USD | 4.55% |
| 1997 FY | 37.6 Million USD | -46.51% |
| 1997 Q2 | 21.4 Million USD | 16.3% |
| 1996 FY | 70.3 Million USD | 24.65% |
| 1996 Q3 | 17.9 Million USD | -9.14% |
| 1996 Q2 | 19.7 Million USD | 30.46% |
| 1996 Q1 | 15.1 Million USD | 7.09% |
| 1996 Q4 | 17.6 Million USD | -1.68% |
| 1995 Q3 | 13.2 Million USD | -21.89% |
| 1995 Q1 | 12.3 Million USD | 0.0% |
| 1995 FY | 56.4 Million USD | 0.0% |
| 1995 Q4 | 14.1 Million USD | 6.82% |
| 1995 Q2 | 16.9 Million USD | 37.4% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | 583.314% |
| Dynavax Technologies Corporation | -37.02 Million USD | 2308.264% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 15618.618% |
| Perrigo Company plc | 151.9 Million USD | -438.299% |
| Illumina, Inc. | -1.06 Billion USD | 176.49% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 88.079% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 277.54% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 105.809% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 58.641% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 839.209% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 79.796% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 1930.604% |
| Biogen Inc. | 1.29 Billion USD | 36.947% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 398.416% |
| Evolus, Inc. | -49.23 Million USD | 1760.829% |
| Adicet Bio, Inc. | -152.03 Million USD | 637.81% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 773.012% |
| bluebird bio, Inc. | -244.26 Million USD | 434.754% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 625.624% |
| FibroGen, Inc. | -281.81 Million USD | 390.146% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 39.431% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 1913.942% |
| Homology Medicines, Inc. | -48.25 Million USD | 1794.49% |
| Geron Corporation | -193.94 Million USD | 521.604% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 389.776% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 1212.575% |
| Myriad Genetics, Inc. | -123.7 Million USD | 761.015% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 910.969% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 258.682% |
| Zoetis Inc. | 3.06 Billion USD | 73.357% |
| Abeona Therapeutics Inc. | -48.2 Million USD | 1796.423% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 24.796% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | -320.527% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 81.017% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 2188.412% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 331.158% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 396.253% |
| Verastem, Inc. | -92.08 Million USD | 987.968% |
| Nektar Therapeutics | -137.42 Million USD | 694.998% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 452.713% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 939.874% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 405.303% |
| OPKO Health, Inc. | -157.02 Million USD | 620.743% |
| Exelixis, Inc. | 170.88 Million USD | -378.495% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | -225.897% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -662.174% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 1566.526% |
| uniQure N.V. | -282.87 Million USD | 389.063% |
| Imunon, Inc. | -21.03 Million USD | 3988.061% |
| Blueprint Medicines Corporation | -486.27 Million USD | 268.15% |
| Insmed Incorporated | -709.62 Million USD | 215.226% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | -142.221% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 308.864% |
| TG Therapeutics, Inc. | 20.63 Million USD | -3862.953% |
| Incyte Corporation | 620.52 Million USD | -31.772% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 212.566% |